Інфаркт міокарда (біохімічні маркери)

19. G. Tatu–Chitoiu, M. Oprisan, O. Cismara et al. Accelerated streptokinase (0.75 MU in 10 minutes) and enoxaparin in the prehospital management of acute myocardial infarction. Eur Heart J 1999; 20 (abstr.suppl.): 517.

20. V. Kakkar, S. Iyengar, F. De Lorenzo et al. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI). Indian Heart J 2000; 52: 533–539.

21. M. Cohen, F. Maritz, G, Gensini et al. The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thronbolyzed: methods and design. J Thromb Thrombolys 2000; 10: 241–246.

22. F. Esteves, J. Braga, M. Rocha et al. Comfirmation that heparins are an alternative to promote early reperfusion – the CHEAPER study. Eur Heart J 1997; 18 (abstr.suppl.): 455.

23. F. Esteves, J. Braga, M. Rocha et al. Comfirmation that heparins are an alternative to promote early reperfusion – the CHEAPER study. Am J Cardiol 1998; 31 (suppl. C): 94C.

24. F. Kontny, J. Dale, U. Abildgaard et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. JACC 1997; 39: 962–969.

25. B. Charbonnier. Fraxiparine and prevention of left ventricular thrombosis in non–thrombolyzed myocardial infarction. FATIV Study. Arch Mal Coeur Vaiss 1997; 90: 1215–1221.

26. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low–molecular–weight heparin during in instability in coronary artery disease. The Lancet 1996; 347: 561–568.

27. W. Klein, A. Buchwald, S. Hillis et al. Comparison of Low–Molecular–Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61–68.

28. The FRAX. I. S. Study Group. Comparison of two treatment durations (6 days and 14 days) of low molecular weight heparin with a 6–day treatment of unfractionated heparin in the initial management of unstable angina or non–Q–wave myocardial infarction: FRAX. I. S. (FRAxiparine in Ischemic Syndrome). Eur Heart J 1999; 20: 1553–1562.

29. M. Cohen, C. Demers, E. Gurfinkel et al. A comparison of low–molecular–weight heрarin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–452.

30. E. Antman, C. McCabe, E. Gurfinkel et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q–Wave Myocardial Infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999:100: 1593–1601.

31. Antman E. M., Cohen M., Radley D. et al. Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q–Wave Myocardial Infarction. TIMI 11B–ESSENCE Meta–Analysis. Circulation 1999:100: 1602–1608.

32. FRISC II Investigators. Long–term low–molecular–mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study. Lancet 1999; 354: 701–707.

33. S. Husted, R. Becker, A. Kher. A Critical Review of Clinical Trials for Low–Molecular–Weight Heparin Therapy in Unstable Coronary Artery Disease. Clin Cardiol 2001; 24: 492–499.34. FRISC II Investigators. Invasive compared with non–invasive treatment in unstable coronary–artery disease: FRISC II prospective randomized multicentre study. Lancet 1999; 354: 708–715.

35. J. Coillet, G. Montalescot, L. Lison, et al. Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris. Circulation 2001; 103: 658–663.

36. M. Rabah, J. Premmereur, M. Graham et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999; 84: 1391–1395.

37. D. Kereiakes, C. Grines, E. Fry et al. Enoxaparin and abxicimab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001; 13: 272–278.

38. K. Karsch, M. Preisack, B. Baildon et al.and REDUCE trial group. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: Results of randomized, double–blind, unfractionated heparin and and placebo–controlled, multicenter trial (REDUCE trial). JACC 1996:28: 1437–1443.

39. D. Dudek, P. Zymek, S. Bartus, et al. Prospective randomized comparison of enoxaparin versus unfractionated heparin for elective percutaneous coronary interventions among ticlopidine–pretreated patients. Eur Heart J 2000; 21: (abstr.suppl): 381.

40. J. Zidar. Low molecular weight heparins in coronary stenting. The ENTICES trial. Am J Cardiol 1998; 82: 29L–32L.